SINGAPORE--(BUSINESS WIRE)--PrIME Biologics Private Limited today announced investments from Xeraya Capital Labuan Ltd via its affiliate, Pulau Manukan Ventures Labuan Ltd, and JP Asia Prime Capital Pte Ltd.
This investment will enable PrIME Biologics to establish the first human blood plasma fractionation plant in South East Asia at its Singapore cGMP facility using its patented PrIME technology. The facility is currently undergoing extensive refurbishment and PrIME will be recommissioning the facility at an opening ceremony on October 8. PrIME Biologics plans to have the facility registered with the Singapore Health Science Authority and fully operational in January 2015.
Help employers find you! Check out all the jobs and post your resume.
